OSI Pharmaceuticals, Inc. Grants License Under Dipeptidyl Peptidase IV (DPIV) Patents

MELVILLE, N.Y.--(BUSINESS WIRE)--Dec. 22, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that its UK subsidiary focused on the discovery and development of diabetes and obesity therapeutics has granted a worldwide non-exclusive license under its DPIV patent portfolio to a major British pharmaceutical company. The portfolio covers the use of DPIV inhibitors for the treatment of type 2 diabetes and related indications. OSI will receive upfront, milestone and royalty payments. Additional financial terms were not disclosed.
MORE ON THIS TOPIC